Floatz Rating
B58/100
Confidence
Indicative
Sponsor
GlaxoSmithKline
Modality
monoclonal_antibody
Development Phase
Phase 2
Status
Active
Evidence ledger · v0.2
Clinical Evidence
Clinical track record: trial progression, reported outcomes, safety signals, and endpoint quality.
54High confidence
Detailed axis rationale is planned and will be published soon.
| Trial | Phase | Status | N | Primary endpoint | Readout |
|---|---|---|---|---|---|
NCT06551142CT.gov A Study of GSK5764227 in Participants With Advanced Solid Tumors (EMBOLD) | — | Recruiting | — | — | — |
NCT05980416CT.gov Study of EO-3021 in Adult Patients With Solid Tumors Likely to Express CLDN18.2 | — | Terminated | — | — | — |
NCT05277051CT.gov First-Time-in-Human Study of GSK4381562 in Participants With Advanced Solid Tumors | — | Active Not Recruiting | — | — | — |
NCT06926673CT.gov Platform Trial of Novel Regimens Versus Standard of Care (SoC) in Participants With Non-small Cell Lung Cancer (NSCLC) - Sub-study 3 | — | Completed | — | — | — |
NCT04544995CT.gov Dose Escalation and Cohort Expansion Study of Niraparib and Dostarlimab in Paediatric Participants With Solid Tumors (SCOOP) | — | Terminated | — | — | — |
NCT04446351CT.gov Study of the Safety and Effectiveness of GSK6097608 in Participants With Advanced Solid Tumors | — | Active Not Recruiting | — | — | — |
NCT04165772CT.gov Study of Induction PD-1 Blockade in Subjects With Locally Advanced Mismatch Repair Deficient Solid Tumors | — | Recruiting | — | — | — |
NCT03843359CT.gov A First Time in Human (FTIH) Study of GSK3745417 Administered to Participants With Advanced Solid Tumors | — | Active Not Recruiting | — | — | — |
NCT03739710CT.gov Platform Trial of Novel Regimens Versus Standard of Care (SoC) in Participants With Non-small Cell Lung Cancer (NSCLC) | — | Completed | — | — | — |
NCT03307785CT.gov Study of Niraparib, TSR-022, Bevacizumab, and Platinum-Based Doublet Chemotherapy in Combination With TSR-042 | — | Completed | — | — | — |
Show 5 more trialsShow fewer
NCT03308942CT.gov Effects of Single Agent Niraparib and Niraparib Plus Programmed Cell Death-1 (PD-1) Inhibitors in Non-Small Cell Lung Cancer Participants | — | Completed | — | — | — |
NCT03250832CT.gov Study of TSR-033 With an Anti-programmed Cell Death-1 Receptor (PD-1) in Participants With Advanced Solid Tumors | — | Completed | — | — | — |
NCT02817633CT.gov A Study of TSR-022 in Participants With Advanced Solid Tumors (AMBER) | — | Active Not Recruiting | — | — | — |
NCT02723955CT.gov Dose Escalation and Expansion Study of GSK3359609 in Participants With Selected Advanced Solid Tumors (INDUCE-1) | — | Completed | — | — | — |
NCT02715284CT.gov Study of TSR-042, an Anti-programmed Cell Death-1 Receptor (PD-1) Monoclonal Antibody, in Participants With Advanced Solid Tumors | — | Active Not Recruiting | — | — | — |
Competitive Position
Competitive setting: how crowded the indication is, class-level failures, and timing against rivals.
65High confidence
Detailed axis rationale is planned and will be published soon.
Same indication · Neoplasm
| Asset | Sponsor | Phase | Rating |
|---|---|---|---|
| Dostarlimab (this asset) | GlaxoSmithKline | P2 | B · 58 |
| Panitumumab | Astellas Pharma Inc | P2 | BBB |
| Granulocyte Colony-Stimulating Factor Lenograstim | Sanofi | P4 | BB |
| Dexmedetomidine | Medical College of Wisconsin | P4 | BB |
| Lidocaine | Medical College of Wisconsin | P4 | BB |
| Relatlimab | Bristol-Myers Squibb | P2 | BB |
| Vitamin D | Tanta University | P4 | BB |
| Glycopyrrolate | Medical College of Wisconsin | P4 | BB |
| Dinitrogen Monoxide | Medical College of Wisconsin | P4 | BB |
+42 more in the Neoplasm cohort
Other indications for Dostarlimab
| Indication | Sponsor | Phase | Rating |
|---|---|---|---|
| Non-Small Cell Lung Carcinoma | — | P3 | BB · 68 |
| Ovarian Carcinoma | — | P3 | BB · 65 |
| Colonic Neoplasm | — | P3 | B · 60 |
Scientific Foundation
Strength of the underlying biology: target validation, tractability, modality fit, and how related mechanisms have fared.
NR
Planned for methodology v0.2.
Development Feasibility
How realistically the program can be executed, drawing on modality precedent, enrollment dynamics, and sponsor delivery.
NR
Planned for methodology v0.2.
Commercial Opportunity
Commercial prize: addressable population, unmet need, and the value case for the indication.
NR
Planned for methodology v0.2.
IP & Exclusivity
Exclusivity position, covering patent protection and freedom-to-operate runway.
NR
Planned for methodology v0.2.
Manufacturing & Supply
Manufacturing and supply readiness, driven by modality process and scale-up risk.
NR
Planned for methodology v0.2.
Related assets
Citation
Floatz Terminal. Dostarlimab in Neoplasm. Methodology v0.2. Rated under v0.2 effective July 8, 2026. Last refreshed July 8, 2026. Accessed July 14, 2026. https://terminal.floatz.ai/assets/dostarlimab-neoplasm
Are you the sponsor?
Submit your data room for a Verified Rating. The public-data rating remains visible alongside.
Contact →